CNS & Neurology
Medicines

CNS & Neurology Medicine Supply for Hospitals & International Buyers

Neurological disorders represent a significant and growing disease burden worldwide. Epilepsy affects approximately 50 million people globally, Parkinson\u0027s disease affects over 10 million, and multiple sclerosis affects around 2.8 million. In the GCC region and across Africa, neurological conditions are increasingly prevalent due to demographic growth, improved diagnostic capacity and rising awareness. Yet access to consistent, quality-assured CNS medicines remains a persistent challenge for many hospitals and healthcare systems in these regions. Euro Biom specialises in sourcing UK-licensed CNS and neurology medicines for export to verified international buyers.

Antiepileptic drugs (AEDs) form a core part of our CNS portfolio. We supply first-generation agents including sodium valproate, carbamazepine, phenytoin and phenobarbital, which remain widely used in many markets due to their established efficacy and low cost. Second and third-generation AEDs available through our network include lamotrigine, levetiracetam, topiramate, oxcarbazepine, lacosamide and zonisamide. Many hospitals in GCC countries and Africa specifically request UK-manufactured or UK-branded versions of these medicines for quality assurance reasons, and Euro Biom can source these from licensed UK wholesalers and manufacturers.

Parkinson\u0027s disease management requires a range of dopaminergic and adjunctive agents, often in combination. We supply levodopa/carbidopa in standard and controlled-release formulations, as well as levodopa/carbidopa/entacapone combinations. Dopamine agonists including pramipexole, ropinirole and rotigotine transdermal patches are available, along with MAO-B inhibitors such as rasagiline and selegiline. For patients with advanced Parkinson\u0027s requiring continuous dopaminergic stimulation, we can source apomorphine and levodopa/carbidopa intestinal gel products through specialist channels. Availability of specific formulations and strengths is a frequent challenge in GCC and African markets, and our sourcing team works to fulfil these requirements from UK supply.

Multiple Sclerosis Therapies and Neurological Biologics

Multiple sclerosis treatment has been transformed by disease-modifying therapies (DMTs), several of which require cold-chain logistics and specialist handling. We supply interferon beta-1a and interferon beta-1b products, glatiramer acetate, and oral DMTs including dimethyl fumarate and fingolimod. For higher-efficacy biological therapies, we can source natalizumab and ocrelizumab through our licensed biologics supply chain. These products require refrigerated storage and GDP-compliant cold chain transport throughout the supply process, which Euro Biom maintains for all shipments to GCC and African destinations. MS therapy demand in the Gulf region is growing, with specialist neurology centres in the UAE, Saudi Arabia and Kuwait prescribing biological DMTs at increasing rates.

Neuropathic pain is a common and often undertreated condition arising from diabetes, herpes zoster, chemotherapy and various neurological conditions. The principal agents used are gabapentin, pregabalin, duloxetine, amitriptyline and capsaicin-based topical treatments. Gabapentin and pregabalin are both widely used for diabetic peripheral neuropathy and post-herpetic neuralgia, conditions with high prevalence in GCC countries given the significant burden of type 2 diabetes in this region. We supply these agents in the strengths and pack sizes most commonly requested by hospital pharmacies and outpatient neurology clinics.

Dementia medicines are increasingly in demand across both GCC and African healthcare systems as ageing populations grow. Acetylcholinesterase inhibitors including donepezil, rivastigmine (oral and transdermal patch) and galantamine are used for mild to moderate Alzheimer\u0027s disease. Memantine, an NMDA receptor antagonist, is used for moderate to severe stages and can be combined with donepezil. Rivastigmine patches require careful storage and handling, and we supply these with full cold-chain documentation to support import and customs clearance. Named patient supply is available for dementia medicines not yet registered in a recipient country\u0027s local formulary.

GCC hospitals, particularly tertiary neurology centres in Saudi Arabia, the UAE and Qatar, frequently encounter situations where specific branded CNS medicines are preferred over generic equivalents, or where a particular formulation is not available locally. UK-licensed medicines carry strong regulatory credibility in GCC import frameworks, and Euro Biom\u0027s MHRA Wholesale Dealer Authorisation provides the documentation required by purchasing hospitals and national health authorities. We can supply certificates of conformity, batch release documentation, summary of product characteristics and cold-chain records for all products. For controlled CNS substances including certain AEDs and opioid adjuncts, we advise on the import licence requirements applicable in each destination country.

Euro Biom provides rapid sourcing and wholesale supply of CNS medicines on both a standard and urgent basis. Our GDP-compliant supply chain covers ambient, refrigerated and controlled-temperature shipments, allowing us to handle the full breadth of the CNS portfolio from oral tablets to injectable biologics and transdermal patches. For CNS medicines not commercially available in a recipient country, we can supply under named patient or special import provisions to verified healthcare institutions. We work with neurology departments, hospital pharmacies, NGO procurement teams and pharmaceutical distributors across the GCC and Africa. Submit an enquiry with your product list and destination, and our team will respond with availability and pricing.